News about Aphaia: learn more about the latest developments around our company, our research and our products here.

Aphaia Pharma Publishes Phase 1 and 2 Clinical Data of Oral Formulation in Patients with Obesity and Prediabetes

• Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases.
• It is currently under evaluation in a Phase 2 trial in individuals with obesity, following positive Phase 2 trial data in patients with prediabetes

Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity

• Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study
• Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of obesity and associated metabolic diseases

Aphaia Pharma to Participate in Panel Discussion at SXSW 2025

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, February 20, 2025 – Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at SXSW, taking place March 7-15, 2025, in Austin, Texas.

Aphaia Pharma to Participate in Panel Discussion at the 1^st Annual BioPharma Obesity Innovation Forum in San Francisco

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, December 19, 2024 – Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 1^st Annual  BioPharma Obesity Innovation Forum, taking place January 11, 2025, in San Francisco, California.

Aphaia Pharma to Participate in a Panel Discussion at the 1^st Annual Obesity & Metabolic Innovation Forum

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, November 25, 2024 – Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 1^st Annual  Obesity & Metabolic Innovation Forum, taking place December 4, 2024, in Boston, Massachusetts.

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment

• Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration
• The results provide proof-of-concept for clinical efficacy of Aphaia’s oral glucose formulation, designed to restore endogenous nutrient-sensing pathways in the gastrointestinal tract
• The study confirms that APHD-012 is well tolerated, with no serious adverse events observed
• Additional results from a Phase 2 trial evaluating Aphaia’s formulation in individuals with obesity are expected in H2 2024

Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity

• Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulation
• Topline data anticipated in Q3 and Q4 2024 for Arm 1 and Arm 2 of the trial, respectively

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity

• Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)
• The company is expanding its trial protocol to further explore the contribution of circadian effects in weight loss treatment with four additional cohorts
• Topline data anticipated in Q3 and Q4 2024 for cohorts 1-2 and 3-6, respectively

Aphaia Pharma to Participate in a Panel Discussion at the 10^th LSX World Congress

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 –
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10^th LSX World Congress, taking place April 29-30, 2024 in London, England.

Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced the first patient has been dosed in a Phase 2 study evaluating the safety and efficacy of its lead candidate, APH-012, to improve glucose tolerance in patients with prediabetes.  

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of metabolic diseases, today announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic diseases, today announced that it has enrolled the first patient as part of a Phase 2 study evaluating the safety and efficacy of its lead drug candidate, APH-012, to induce weight loss in individuals with obesity.